Niagen Bioscience, Inc. — Director's Dealing 2015

Jul 7, 2015

SEC Form 4 — Statement of Changes in Beneficial Ownership

Issuer: ChromaDex Corp. (CDXC.OB)
CIK: 0001386570
Period of Report: 2015-07-06

Reporting Person: Allen Stephen R. (N/A)

Derivative Transactions

Date	Security	Exercise Price	Code	Shares	A/D	Expiration	Underlying	Ownership
2015-07-06	Employee Stock Options (right to buy)	$1.22	A	102500	Acquired	2025-07-06	Common Stock (102500)	Direct

Footnotes

F1: Options vest 1/12th every month for 12 months and will be fully vested on July 6, 2016.

F2: The total includes 282,500 options under different terms.